Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.47 |
| ▸ | MMP8 | P22894 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | CPA1 | P15085 | 2/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | FCER2 | P06734 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897044 | 1.00 | ACACB (0.54) | ACACBTACR1MMP9MMP8HTR2A | |
| SCHEMBL2194578 | 0.84 | CTSC (0.53) | ACACBMMP9MMP8HTR2AHTR2C | |
| SCHEMBL8581105 | 0.84 | TACR1 (0.50) | ACACBTACR1MMP9MMP8MME | |
| SCHEMBL7367584 | 0.83 | CTSS (0.64) | TACR1MMP9MMP8ACECTSB | |
| SCHEMBL5051890 | 0.83 | CTSS (0.64) | TACR1MMP9MMP8ACECTSB | |
| SCHEMBL2638638 | 0.82 | HTR2A (0.51) | ACACBMMP9MMP8HTR2AHTR2C | |
| SCHEMBL2843211 | 0.82 | CTRB1 (0.57) | ACACBTACR1CTSCCTSSCTSK | |
| SCHEMBL334424 | 0.82 | CTRB1 (0.57) | ACACBTACR1CTSCCTSSCTSK | |
| SCHEMBL334301 | 0.82 | CTRB1 (0.57) | ACACBTACR1CTSCCTSSCTSK | |
| SCHEMBL27922312 | 0.81 | ACACB (0.73) | ACACBTACR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-0683792-B1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LAB (US) | 2001-09-26 | — | — | EP | claimed |
| EP-0673254-A4 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| EP-0683792-A4 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| US-5698522-A | INHIBIT RELEASE OF LUTEINIZING HORMONE RELEASING HORMONE | ABBOTT LABORATORIES (US) | 1997-12-16 | — | — | US | claimed |
| JP-H08505611-A | — | — | 1996-06-18 | — | — | JP | claimed |
| JP-H08504209-A | — | — | 1996-05-07 | — | — | JP | claimed |
| EP-0683792-A1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LABORATORIES (US) | 1995-11-29 | — | — | EP | claimed |
| EP-0673254-A1 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1995-09-27 | — | — | EP | claimed |
| WO-1994014841-A1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1994013313-A1 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1994-06-23 | — | — | WO | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-1765295-B2 | A PROCESS FOR PRODUCING A SUSTAINED-RELEASE MICROCAPSULE | TAKEDA PHARMACEUTICAL (JP) | 2015-09-09 | — | — | EP | disclosed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | disclosed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | ACACB 806/4885TACR1 227/4885MMP9 673/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | ACACB 806/4885TACR1 227/4885MMP9 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.